Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Lechleiter to chairman

Executive Summary

Lilly CEO John Lechleiter assumes the added role of chairman of the board effective Jan. 1, 2009, succeeding Sidney Taurel, who will become chairman emeritus. The move completes the transition in the company's top management. Lechleiter succeeded Taurel as CEO in April (1"The Pink Sheet," Jan. 7, 2008, p. 10). Taurel has served as Lilly's chairman since 1999, following his appointment as CEO in 1998. Lechleiter, a 28-year veteran of the company, was appointed president and chief operating officer in 2005

You may also be interested in...



Lilly Leadership Falls To Lechleiter In ’08 As Taurel Resigns As CEO

The appointment of Lilly President and Chief Operating Officer John Lechleiter to CEO should be a smooth transition in early 2008 when longtime chief exec Sidney Taurel retires

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel